(Q48484232)

11 February 2018

title

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. (English)

1 reference

11 February 2018

0 references

1 reference

2

Toshifumi Hibi

1 reference

11 February 2018

Mamoru Watanabe

1

object named as

Mamoru Watanabe

1 reference

11 February 2018

Jingdong Chao

5

object named as

Jingdong Chao

1 reference

11 February 2018

Anne Camez

7

object named as

Anne Camez

1 reference

11 February 2018

author name string

Kathleen G Lomax

3

1 reference

11 February 2018

Susan K Paulson

4

1 reference

11 February 2018

M Shamsul Alam

6

1 reference

11 February 2018

Study Investigators

8

1 reference

11 February 2018

publication date

26 August 2011

1 reference

11 February 2018

Journal of Crohn's and Colitis

published in

1 reference

11 February 2018

volume

6

1 reference

11 February 2018

issue

2

1 reference

11 February 2018

page(s)

160-173

1 reference

11 February 2018

Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Crohn's disease: Adalimumab improves quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.013

10.1016/J.CROHNS.2011.07.013

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018